ANI Pharmaceuticals
ANIP
230 hedge funds and large institutions have $1.35B invested in ANI Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 63 increasing their positions, 76 reducing their positions, and 20 closing their positions.
135% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 20
27% more capital invested
Capital invested by funds: $1.07B → $1.35B (+$284M)
12% more funds holding
Funds holding: 205 → 230 (+25)
0.16% more ownership
Funds ownership: 91.85% → 92.01% (+0.16%)
17% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 76
38% less call options, than puts
Call options by funds: $535K | Put options by funds: $863K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$12.6M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$10.8M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$9.94M |
| 4 |
JP Morgan Chase
New York
|
+$9.24M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$19.7M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$11.8M |
| 3 |
Millennium Management
New York
|
-$11M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.94M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$6.8M |
ANIP Hedge Fund Activity: Q1 2025 in Review
230 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2025, worth a combined $1.35B — up 27% from $1.07B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new ANIP positions and 20 closed out — a net gain of 27 holders — while 63 added to existing stakes and 76 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $12.6M. The largest seller was UBS Group, cutting an estimated $19.7M.
- 230 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2025, up from 205 in Q4 2024.
- Funds reported $1.35B of ANI Pharmaceuticals stock for Q1 2025, up 27% quarter-over-quarter.
- 47 funds opened new ANI Pharmaceuticals positions in Q1 2025 and 20 closed out, a net change of +27 holders.
- The largest ANI Pharmaceuticals buyer in Q1 2025 was Morgan Stanley, an estimated $12.6M added.
- The largest ANI Pharmaceuticals seller in Q1 2025 was UBS Group, an estimated $19.7M sold.
Based on aggregated 13F filings for Q1 2025.